Rosiglitazone, but not ramipril, prevents onset of type 2 diabetes in high-risk patients
This article has no abstract so we have provided the first paragraph of the full text.
An international team of investigators has evaluated the effects of rosiglitazone, an antihyperglycemic drug, and ramipril, an angiotensin-converting-enzyme inhibitor, on the development of diabetes in a double-blind, placebo-controlled, randomized, multicenter trial. Results for each drug were reported separately.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
Chemical biology Dressed-up proteinsNature News and Views (26 Apr 2007)
